Metformin, a staple of glucose management for decades, is now being studied for use in a wide range of diseases from carotid atherosclerosis to vitiligo.
GLP-1 agonists could be a treatment option to reduce the risk for major adverse liver outcomes in adults with type 2 diabetes and chronic liver disease.